BioFire Diagnostics Inc. has raised $25 million in new funding from New York-based Athyrium Opportunities Fund. The money will be used to help commercialize the company’s “FilmArray” diagnostic ...

SALT LAKE CITY--(BUSINESS WIRE)--BioFire Diagnostics, Inc. today announced that it has submitted the FilmArray Blood Culture Identification (BCID) Panel to the U.S. Food and Drug Administration (FDA) ...

SALT LAKE CITY--(BUSINESS WIRE)--BioFire Diagnostics, Inc., today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,394,608 covering the company’s FilmArray ...

SALT LAKE CITY, May 2, 2013 /PRNewswire/ -- BioFire Diagnostics, Inc. today announced the expansion of its financing commitment with Athyrium Opportunities Fund to $45 million from $25 million. The ...

BioFire Diagnostics won 510(k) clearance for its gastrointestinal panel for infectious diarrhea, following in the footsteps of the company's acquisition by French diagnostic giant bioMérieux.

SALT LAKE CITY, Utah (March 26, 2013) — BioFire Diagnostics, Inc. today announced that it has signed a competitive prototyping contract with the Department of the Army for Increment 1 of the Next ...

France-based bioMérieux has acquired the privately held US company, BioFire Diagnostics Inc for $400 million, consolidating its position as a major player in infectious disease diagnostics. BioFire ...

bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for ...

Infection of the meninges surrounding the brain and spinal cord (meningitis), or of the brain (encephalitis) can have high mortality and morbidity rates depending on the source of infection. Acute ...

The US Food and Drug Administration (FDA) allowed Salt Lake City, Utah-based BioFire Diagnostics to market the first cerebrospinal fluid (CSF) nucleic acid-based test for simultaneous detection of ...